Intercure (TA:INCR) — Market Cap & Net Worth
Market Cap & Net Worth: Intercure (INCR)
Intercure (TA:INCR) has a market capitalization of $171.47 Million (ILA63.96 Billion) as of October 10, 2026. Listed on the TA stock exchange, this Israel-based company holds position #17180 globally and #204 in its home market, demonstrating a -0.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intercure's stock price ILA1653.00 by its total outstanding shares 59228556 (59.23 Million).
Intercure Market Cap History: 2015 to 2026
Intercure's market capitalization history from 2015 to 2026. Data shows growth from $24.73 Million to $262.48 Million (24.13% CAGR). Check Intercure (INCR) stock price for real-time trading data and today's change.
Intercure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intercure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Intercure for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.19x
Intercure's market cap is 0.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $262.04 Million | $8.93 Million | -$5.89 Million | 29.36x | N/A |
| 2020 | $259.64 Million | $65.03 Million | -$37.23 Million | 3.99x | N/A |
| 2021 | $329.01 Million | $219.68 Million | $4.69 Million | 1.50x | 70.15x |
| 2022 | $191.82 Million | $388.68 Million | $44.82 Million | 0.49x | 4.28x |
| 2023 | $73.44 Million | $355.55 Million | -$61.96 Million | 0.21x | N/A |
| 2024 | $94.48 Million | $238.84 Million | -$67.80 Million | 0.40x | N/A |
| 2025 | $51.29 Million | $270.20 Million | -$35.71 Million | 0.19x | N/A |
Competitor Companies of INCR by Market Capitalization
Companies near Intercure in the global market cap rankings as of October 10, 2026. See how leveraged is Intercure's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Intercure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Intercure Historical Marketcap From 2015 to 2026
Between 2015 and today, Intercure's market cap moved from $24.73 Million to $ 262.48 Million, with a yearly change of 24.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA262.48 Million | +411.76% |
| 2025 | ILA51.29 Million | -45.71% |
| 2024 | ILA94.48 Million | +28.65% |
| 2023 | ILA73.44 Million | -61.71% |
| 2022 | ILA191.82 Million | -41.70% |
| 2021 | ILA329.01 Million | +26.72% |
| 2020 | ILA259.64 Million | -0.92% |
| 2019 | ILA262.04 Million | -26.70% |
| 2018 | ILA357.49 Million | +1267.57% |
| 2017 | ILA26.14 Million | -33.21% |
| 2016 | ILA39.14 Million | +58.29% |
| 2015 | ILA24.73 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Intercure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $171.47 Million USD |
| MoneyControl | $171.47 Million USD |
| MarketWatch | $171.47 Million USD |
| marketcap.company | $171.47 Million USD |
| Reuters | $171.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more